Atossa Genetics (ATOS) Receiving Somewhat Positive News Coverage, Accern Reports
News articles about Atossa Genetics (NASDAQ:ATOS) have trended somewhat positive on Sunday, Accern reports. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Atossa Genetics earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.7507096625491 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
- Global Estrogen Receptor Beta Market Research Report H2 2017: Drug Profile, Top Industry Intelligence and Therapeutic Development (gmoutlook.com)
- Atossa Genetics (ATOS) Stock: Continues Skyward On Breast Cancer News (cnafinance.com)
- Atossa Genetics Announces Chimeric Antigen Receptor Therapy (CAR-T) Program in Breast Cancer (nasdaq.com)
- Atossa Genetics (ATOS) Stock: Gaining On Breast Cancer Update (cnafinance.com)
- Atossa Genetics to Present at The MicroCap Conference in New York City on October 5, 2017 (finance.yahoo.com)
Atossa Genetics (ATOS) traded down 6.7734% during midday trading on Friday, hitting $0.5299. The company had a trading volume of 1,715,073 shares. The company’s 50 day moving average is $0.50 and its 200 day moving average is $0.54. The stock’s market cap is $6.20 million. Atossa Genetics has a 12-month low of $0.32 and a 12-month high of $2.60.
Atossa Genetics (NASDAQ:ATOS) last announced its earnings results on Monday, August 14th. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.44) by ($0.20). On average, equities analysts anticipate that Atossa Genetics will post ($3.57) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/08/atossa-genetics-atos-receiving-somewhat-positive-news-coverage-accern-reports.html.
Atossa Genetics Company Profile
Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.
Receive News & Stock Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related stocks with our FREE daily email newsletter.